DAZALS: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Of Dazucorilant, A Selective Glucocorticoid Receptor Modulator, In Amyotrophic Lateral Sclerosis

Summary

No impact to ALSFRS-R: DAZALS did not achieve its primary endpoint of slowing functional decline as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) scale
Survival improved by dazucorilant 300 mg: Secondary and exploratory endpoints showed improvement in overall survival for patients who received dazucorilant 300 mg, including those treated for >24 weeks
Tolerability: Dazucorilant-treated patients discontinued at higher rates than placebo-treated patients due to abdominal pain, which occurred in the first 3–5 weeks. Abdominal pain resolved following treatment interruption and with time in patients who continued treatment
No additional serious or severe AEs: Dazucorilant-treated patients showed similar rates of serious and severe adverse events (AEs) compared to placebo-treated patients

Scientific journal publications or scientific congress presentations may include information regarding investigational products or uses.